MedPath

Comparison of efficacy and safety of Vildagliptin and Teneligliptin in patients with Type 2 Diabetes Mellitus

Not Applicable
Conditions
Health Condition 1: null- Type 2 Diabetes Mellitus
Registration Number
CTRI/2017/02/007766
Lead Sponsor
jawaharlal nehru medical college and hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
160
Inclusion Criteria

Newly diagnosed type 2 Diabetes mellitus

poorly controlled diabetics on oral hypoglycemic agents

Exclusion Criteria

Type 1 DM

Patients on insulin

Diabetic Ketoacidosis

Diabetic Nephropathy

CHF

Septicaemia

Psychotic Patients

Pregnancy

Known case of HIV/HBs Ag/HCV and immunocompromised patients

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Glycated Haemoglobin <br/ ><br>Timepoint: 0,12.24 weeks <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Fasting and Post prandial plasma GlucoseTimepoint: 0,6,12,18,24 weeks
© Copyright 2025. All Rights Reserved by MedPath